Flag of the European Union EU Clinical Trials Register Help

Clinical trials for DNA synthesis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: DNA synthesis. Displaying page 1 of 1.
    EudraCT Number: 2007-003111-31 Sponsor Protocol Number: 2007-1-18-20-6 Start Date*: 2008-07-21
    Sponsor Name:Charité - Universitaetsmedizin Berlin
    Full Title: Influence of postoperative influenza vaccination versus GM-CSF in immune-compromised patients undergoing pancreatic or esophageal resection on the course of immunosuppression and the postoperative ...
    Medical condition: Post-operative immunological stimulation in severe immune suppression. The study population is made up of adult, which are able to give their inform consent by their own. The patients are undergoin...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002183-18 Sponsor Protocol Number: QLK3-2002-02003 Start Date*: 2004-11-05
    Sponsor Name:Institut Gustav Roussy
    Full Title: ESOPE (QLK3-2002-02003) European Standard Operating Procedures for Electrochemotherapy and Electrogenetherapy
    Medical condition: subcutaneous or cutaneous metastases from any primary cancer, which are recurrent, progressive, inoperable and which have proven refractory to the conventional therapies of surgery and/or chemother...
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000582-47 Sponsor Protocol Number: CLL2-BCG Start Date*: 2015-04-15
    Sponsor Name:University of Cologne
    Full Title: A prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab) and CAL-101 (idelalisib) followed ...
    Medical condition: Fit and unfit patients with relapsed/refractory CLL requiring Treatment (including relapsed/refractory patients enrolled before the second amendment and relapsed high-risk patients recruited after...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-009154-25 Sponsor Protocol Number: omalizumab/2009/01 Start Date*: 2009-07-07
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St.Thomas' NHS Foundation Trust
    Full Title: The effect of a humanised monoclonal anti-IgE antibody (omalizumab) on disease control and bronchial mucosal inflammation in non-atopic (“intrinsic”) asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002770-27 Sponsor Protocol Number: DRA-104-001 Start Date*: 2021-07-12
    Sponsor Name:Dracen Pharmaceuticals, Inc.
    Full Title: Phase 1 and phase 2a, first-in-human study of DRP-104, a glutamine antagonist, in adult patients with advanced solid tumors
    Medical condition: Cancer, advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003204-40 Sponsor Protocol Number: PATHBP_2013 Start Date*: 2014-01-20
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: Paracetamol treatment in hypertension: effect on blood pressure
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10005729 Blood pressure ambulatory PT
    14.1 10047065 - Vascular disorders 10020775 Hypertension arterial LLT
    14.1 10022891 - Investigations 10005756 Blood pressure systolic PT
    14.1 10047065 - Vascular disorders 10020772 Hypertension PT
    14.1 10022891 - Investigations 10005735 Blood pressure diastolic PT
    14.1 10022891 - Investigations 10033762 Paracetamol LLT
    14.1 10022891 - Investigations 10005727 Blood pressure PT
    14.1 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-000601-27 Sponsor Protocol Number: MERCURY Start Date*: 2022-09-27
    Sponsor Name:Fondazione GONO
    Full Title: Window-of-opportunity study of chemo-immunotherapy in patients with resectable Merkel Cell Carcinoma prior to surgery: the MERCURY trial
    Medical condition: The disease under clinical investigation is represented by resectable Merkel Cell Carcinoma (MCC), stage IIA-III (according to the AJCC staging system 8th edition). The study will include patients ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10064025 Merkel cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023801-36 Sponsor Protocol Number: RVX222-CS-007 Start Date*: 2011-09-26
    Sponsor Name:Resverlogix Corp.
    Full Title: Phase IIb multi-center, double-blind, randomized, parallel group, placebo-controlled clinical trial for the assessment of coronary plaque changes with RVX000222, as determined by intravascular ultr...
    Medical condition: Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    13.1 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005091-36 Sponsor Protocol Number: 2020-005091-36 Start Date*: 2021-08-30
    Sponsor Name:Stichting Catharina Hospital
    Full Title: Signal TrAnsduction Pathway activity analysis for OVarian cancER treatment. STAPOVER study
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033131 Ovarian carcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070905 Ovarian cancer stage I PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070906 Ovarian cancer stage II PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007107 Cancer of ovary LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026310 Malignant neoplasm of ovary LLT
    Population Age: Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Oct 26 06:17:21 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA